![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Sanofi Gains Priority Review for Investigational Treatment for Pompe Disease
Sanofi Gains Priority Review for Investigational Treatment for Pompe Disease
![Sanofi-logo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images/Sanofi-logo.gif?t=1604968321&width=430)
November 20, 2020
The FDA has granted a Priority Review to Sanofi's biologics license application (BLA) for an experimental enzyme-replacement therapy for patients suffering from Pompe disease, a rare illness that causes muscle deterioration and reduced lung capacity.
The agency's decision to accelerate its review of avalglucosidase alfa was supported by promising data from two clinical trials. In a phase 3 study, the investigational therapy was compared to the standard of care (alglucosidase alfa) in patients with late-onset Pompe disease. A separate phase 2 study assessed the therapy in patients with infantile-onset Pompe disease who were previously treated with alglucosidase alfa.
The FDA has set a target decision date of May 18, 2021 for the BLA. The drug has also received both Breakthrough Therapy and Fast-Track designations.
Upcoming Events
-
21Oct